Results 121 to 130 of about 38,148 (251)

Editorial: Frontiers in malaria research

Frontiers in Microbiology, 2023
Ritu Gill, Rachna Hora, Mahmood M. Alam, Abhisheka Bansal, Tarun Kumar Bhatt, Ashwani Sharma   +5 more
doaj   +1 more source

Skin Fragility and Hyperpigmentation in a Patient With HIV

JEADV Clinical Practice, EarlyView.
Catalina Retamal, Maximiliano Maass, María Fernanda Martin   +2 more
wiley   +1 more source

Novel Histopathologic Features of Diffuse Blue‐Gray Hyperpigmentation Associated With Kratom Use: A Case Report and Literature Review

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Background Drug‐induced hyperpigmentation accounts for 10%–20% of acquired pigmentary disorders and can be misdiagnosed for other causes such as melasma, post inflammatory changes, or heavy metal deposition. Kratom (Mitragyna speciosa), a Southeast Asian plant with an opioid‐like profile, has been increasingly used in the United States for ...
Rita Kamoua, Kristen Paradine, Craig A. Rohan, Mary McDaniel, Diane Perkins   +4 more
wiley   +1 more source

PEG400 regulates Falcipain 2 activity through an allosteric mechanism

The FEBS Journal, EarlyView.
Falcipain‐2 can potentially be leveraged as a drug target due to its critical role as a haemoglobinase during the intra‐erythrocytic stage of Plasmodium falciparum. Here, we investigate the regulation of the proteolytic and haemoglobinase activity of falcipain‐2 in the presence of polyethylene glycol.
Bikram Nath, Subhoja Chakraborty, Sampa Biswas   +2 more
wiley   +1 more source

Tissue Resident Memory Cells: Friend or Foe?

Immunology, EarlyView.
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude, Jude E. Uzonna, Janilyn Arsenio   +2 more
wiley   +1 more source

Gingival and Periodontal Diseases and Conditions in Children and Adolescents: Consensus Report

Journal of Clinical Periodontology, EarlyView.
ABSTRACT Background The objectives of this Focused Workshop were to update the epidemiology, aetiology, risk factors, diagnosis and management of gingival and periodontal diseases and conditions in children and adolescents, and to explore the applicability of the 2018 Classification in children and adolescents.
Iain Chapple, Sotiria Gizani, Mariano Sanz, Dominique Declerck, Phoebus Madianos, Valerie Clerehugh, Monique Danser, Esti Davidovich, Janet Davies, Nikos Donos, Elisabeth Dursun, Elena Figuero, Filippo Graziani, Mervi Gursoy, Soren Jepsen, Clara Joseph, Moritz Kebschull, Norbert Kraemer, Tina Lambrinaki, Rodrigo López, David J. Manton, Joerg Meyle, Ana Molina, Lior Shapira, Cheryl Somani, Georgios Tsilingaridis, Svante Twetman, Nicola West, Biniyam Wondimu, Ferranti Wong, David Herrera   +30 more
wiley   +1 more source

From the Proteome to Therapeutics: A Multi‐Database Approach to Drug Discovery in Periodontitis—An Exploratory Pilot Study

Journal of Clinical Periodontology, EarlyView.
ABSTRACT Introduction This explanatory pilot study presents a workflow to identify approved drugs, which could be repurposed for periodontitis therapy using salivary proteomics combined with drug‐target database screening. Methods Proteomic analyses of saliva using LC–MS/MS were conducted in two independent settings: a cohort (sub‐study I, N = 187) and
Taisir Bozo, Annette Murr, Birte Holtfreter, Sebastian‐Edgar Baumeister, Peter Meisel, Uwe Völker, Werner Weitschies, Henry Völzke, Philipp Kanzow, Elke Hammer, Manuela Gesell Salazar, Thomas Kocher   +11 more
wiley   +1 more source

Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Our findings show that greater proportions of litifilimab‐treated participants than placebo experienced 20%, 50%, 70% or 90% improvements in CLASI‐A score from baseline and CLASI‐A scores of 0–1 or 0–3. Similar results were observed using physician global assessments, supporting the Phase 2 LILAC study primary analysis in CLE.
Victoria P. Werth, Joseph F. Merola, Richard Furie, Kenneth Kalunian, Ronald F. van Vollenhoven, Juanita Romero‐Diaz, Qianyun Li, Weihong Yang, Catherine Barbey   +8 more
wiley   +1 more source

Therapeutic Efficacy of Sulfadoxine-Pyrimethamine and Prevalence of Resistance Markers in Tanzania Prior to Revision of Malaria Treatment Policy: Plasmodium Falciparum Dihydrofolate Reductase and Dihydropteroate Synthase Mutations in Monitoring in Vivo Resistance. [PDF]

, 2004
Prior to the 2001 malarial treatment policy change in Tanzania, we conducted trials to assess the efficacy of sulfadoxine-pyrimethamine (SP) and the usefulness of molecular markers in monitoring resistance.
Abdulla, Salim, Beck, Hans-Peter, Kataraihya, Johannes, Lemnge, Martha, Malisa, Allen, Mshinda, Hassan, Mugittu, Kefas, Mwita, Alex, Ndejembi, Modesta, Nkya, Watoky, Premji, Zulfikar   +10 more
core   +1 more source

Parasomnias and sleep‐related movement disorders induced by drugs in the adult population: a review about iatrogenic medication effects

Journal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont, Vanessa Bloch, Agnès Lillo‐Lelouet, Christine Le Beller, Pierre A. Geoffroy, Marc Veyrier   +5 more
wiley   +1 more source